\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes HealthThe results of the evaluation are:
Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs - HORIZON-HLTH-2022-DISEASE-06-02-two-stage
Vaccines 2.0 - developing the next generation of vaccines - HORIZON-HLTH-2022-DISEASE-06-03-two-stage
Development of new effective therapies for rare diseases - HORIZON-HLTH-2022-DISEASE-06-04-two-stage
In accordance with General Annex D of the Work Programme, the evaluation of the first-stage proposals was made looking only at the criteria 'excellence' and 'impact'. The threshold for both individual criteria is 4. The overall threshold applying to the sum of the two individual scores was set at a level that ensures the total requested budget of proposals admitted to stage 2 is as close as possible to three times the available budget, and not less than two and a half times the available budget, and is as follows:
Source: Funding & Tenders Portal (Funding Updates)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
